Archive for September, 2014

abuzz over there…


Something’s up in Europe that has to do with Data Transparency. I don’t know enough about how the European Union works to understand it, but here’s why I say that something’s buzzing: Jean-Claude Juncker Names European Commissioners New York Times By JAMES KANTER SEPTEMBER 10, 2014 BRUSSELS — Jean-Claude Juncker, the incoming president of the […]

at the wrong meeting…


In the Neuroanatomy I took in the 1960s, we learned the tracts of the peripheral nerves, the spinal cord, the cranial nerves, the motor/sensory systems. It was like the wiring diagrams of my stero-building, ham radio days and I took to it like a duck to water. It was aimed at clinical neurology and grand […]



Uncovering the Hidden Risk Architecture of the Schizophrenias: Confirmation in Three Independent Genome-Wide Association Studies by Javier Arnedo, M.S.; Dragan M. Svrakic, M.D., Ph.D.; Coral del Val, Ph.D.; Rocío Romero-Zaliz, Ph.D.; Helena Hernández-Cuervo, M.D.; Molecular Genetics of Schizophrenia Consortium; Ayman H. Fanous, M.D.; Michele T. Pato, M.D.; Carlos N. Pato, M.D., Ph.D.; Gabriel A. de […]

the other guy…


The gist of this posting by the APA president is a complaint that the current SAMHSA Strategic Plan leaves out the medical specialty of psychiatry. And he correctly notes the influence of the Recovery movement in the SAMHSA document: SAMHSA Strategic Plan Falls Short on Serious Mental Illness From the President PsychiatricNews by Paul Summergrad […]

beyond not inert…


I kind of liked writing the last post [about my connectomes…] and particularly the discussion that followed. I realize that over the recent years, I’ve written a lot about Clinical Trials, but my focus has been on the ways they’ve been misreported or distorted in the service of commerce. I’ve learned a lot about bias […]

about my connectomes

While I haven’t thought about it very much, I made a move from the hardest of medical sciences to the softest without any transition. The first time around was in a lab with scintillation counters printing data to punch cards to feed into Fortran programs that cranked out ANOVA with p values. And then I […]

in need of another British Invasion

UK Agency Will Ask Regulators for Trial Data if Drug Makers Refuse Pharmalot: WSJ by Ed Silverman September 11, 2014 In yet another sign of frustration with drug makers that do not release clinical trial data, the U.K. agency that is responsible for recommending coverage of medicines will ask European regulators for data if companies […]

in praise of monotonous clinical trial reports…

I’ve noticed that there’s a pattern in this blog [and in your responses]. I write a post, and something sticks in my mind, and I chase it in the next. That often goes on for a couple of iterations. It’s apparently how I think. Readers tend to comment the first time around, then run out […]

in praise of anonymous, contactable members of the public

Ed Silverman reports here on the end of a long story that has appeared in fragments for several years. It’s about Agomelatine, a Melatonin like compound, and a review article published in the Lancet by Ian Hickie and Naomi Rodgers at the end of 2011. Here’s the Pharmalot post: Servier Breached Industry Codes by Not […]

note to self…

My last post about Zoloft® and it’s approval [an echo that needs to keep reverberating…] got me thinking about a number of things. In the UPDATE, I finally found that Laura A. Plumlee et. al. v. Pfizer had been denied on a technicality for the second time just this week. I also found a Louisiana […]